This chapter discusses evolution and current status of percutaneous aortic valve implantation and therapies. Current indications for transcatheter aortic valve implantation (TAVI) were specified in the European and US Guidelines in 2012 and 2014, respectively. Briefly, TAVI can be performed in patients with severe AS without surgical option, and as an alternative to surgery in high-risk patients in whom TAVI is favored by the heart team based on the individual risk profile and anatomic suitability. Expansion of clinical indications and further growth of the procedure can be anticipated in the not so distant future.